Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ERAS |
---|---|---|
09:32 ET | 218667 | 2.94 |
09:34 ET | 589 | 2.96 |
09:36 ET | 200 | 2.96 |
09:38 ET | 4207 | 2.92 |
09:41 ET | 1300 | 2.935 |
09:43 ET | 2007 | 2.93 |
09:45 ET | 543 | 2.9199 |
09:48 ET | 200 | 2.915 |
09:50 ET | 3655 | 2.9 |
09:52 ET | 2887 | 2.9 |
09:54 ET | 400 | 2.91 |
09:56 ET | 1428 | 2.9 |
09:57 ET | 100 | 2.905 |
09:59 ET | 300 | 2.9099 |
10:01 ET | 900 | 2.915 |
10:03 ET | 200 | 2.915 |
10:06 ET | 2520 | 2.9 |
10:08 ET | 1234 | 2.895 |
10:10 ET | 2490 | 2.895 |
10:12 ET | 1722 | 2.89 |
10:14 ET | 989 | 2.895 |
10:15 ET | 200 | 2.895 |
10:17 ET | 100 | 2.895 |
10:19 ET | 4138 | 2.89 |
10:21 ET | 20234 | 2.8789 |
10:24 ET | 700 | 2.87 |
10:26 ET | 24184 | 2.88 |
10:28 ET | 2798 | 2.89 |
10:30 ET | 100 | 2.895 |
10:32 ET | 394 | 2.895 |
10:33 ET | 700 | 2.8991 |
10:35 ET | 24244 | 2.905 |
10:37 ET | 500 | 2.905 |
10:39 ET | 25388 | 2.9 |
10:42 ET | 790 | 2.905 |
10:44 ET | 300 | 2.91 |
10:46 ET | 7294 | 2.905 |
10:48 ET | 4784 | 2.91 |
10:50 ET | 1500 | 2.91 |
10:51 ET | 2863 | 2.905 |
10:53 ET | 2090 | 2.905 |
10:55 ET | 2111 | 2.91 |
10:57 ET | 1200 | 2.91 |
11:00 ET | 1400 | 2.91 |
11:02 ET | 2413 | 2.9 |
11:04 ET | 6728 | 2.89 |
11:06 ET | 6616 | 2.9 |
11:08 ET | 1427 | 2.895 |
11:09 ET | 1522 | 2.895 |
11:11 ET | 4517 | 2.885 |
11:13 ET | 1911 | 2.885 |
11:15 ET | 1200 | 2.885 |
11:18 ET | 3709 | 2.88 |
11:20 ET | 600 | 2.885 |
11:22 ET | 1038 | 2.885 |
11:24 ET | 3966 | 2.875 |
11:26 ET | 600 | 2.875 |
11:27 ET | 3416 | 2.885 |
11:29 ET | 200 | 2.88 |
11:31 ET | 4299 | 2.875 |
11:33 ET | 4685 | 2.865 |
11:36 ET | 2178 | 2.875 |
11:38 ET | 1100 | 2.88 |
11:42 ET | 300 | 2.885 |
11:44 ET | 600 | 2.89 |
11:45 ET | 2184 | 2.885 |
11:47 ET | 1601 | 2.885 |
11:49 ET | 7542 | 2.885 |
11:51 ET | 200 | 2.88 |
11:54 ET | 5295 | 2.875 |
11:56 ET | 600 | 2.87 |
11:58 ET | 991 | 2.87 |
12:00 ET | 1200 | 2.87 |
12:02 ET | 6762 | 2.865 |
12:03 ET | 1500 | 2.865 |
12:05 ET | 2376 | 2.86 |
12:07 ET | 35506 | 2.845 |
12:09 ET | 3472 | 2.845 |
12:12 ET | 29735 | 2.85 |
12:14 ET | 3562 | 2.85 |
12:16 ET | 1600 | 2.845 |
12:18 ET | 1457 | 2.845 |
12:20 ET | 2750 | 2.845 |
12:21 ET | 150814 | 2.89 |
12:23 ET | 43897 | 2.9 |
12:25 ET | 200 | 2.895 |
12:27 ET | 505 | 2.895 |
12:30 ET | 1100 | 2.895 |
12:32 ET | 7088 | 2.9 |
12:34 ET | 46998 | 2.9 |
12:36 ET | 1407 | 2.9 |
12:38 ET | 3434 | 2.905 |
12:39 ET | 1517 | 2.905 |
12:41 ET | 25587 | 2.89 |
12:43 ET | 10183 | 2.875 |
12:45 ET | 1500 | 2.875 |
12:48 ET | 1461 | 2.875 |
12:50 ET | 8087 | 2.885 |
12:52 ET | 3675 | 2.89 |
12:54 ET | 4955 | 2.9 |
12:56 ET | 26271 | 2.89 |
12:57 ET | 1200 | 2.885 |
12:59 ET | 600 | 2.885 |
01:01 ET | 1247 | 2.88 |
01:03 ET | 4817 | 2.87 |
01:06 ET | 2331 | 2.865 |
01:08 ET | 1100 | 2.86 |
01:10 ET | 2279 | 2.865 |
01:12 ET | 11365 | 2.86 |
01:14 ET | 1100 | 2.85 |
01:15 ET | 3718 | 2.845 |
01:17 ET | 3717 | 2.84 |
01:19 ET | 1634 | 2.845 |
01:21 ET | 10956 | 2.865 |
01:24 ET | 18470 | 2.845 |
01:26 ET | 956 | 2.845 |
01:28 ET | 5810 | 2.845 |
01:30 ET | 4490 | 2.85 |
01:32 ET | 500 | 2.86 |
01:33 ET | 2939 | 2.86 |
01:35 ET | 6592 | 2.87 |
01:37 ET | 3300 | 2.87 |
01:39 ET | 3200 | 2.87 |
01:42 ET | 2703 | 2.87 |
01:44 ET | 7546 | 2.88 |
01:46 ET | 4113 | 2.88 |
01:48 ET | 22467 | 2.865 |
01:50 ET | 400 | 2.865 |
01:51 ET | 3173 | 2.875 |
01:53 ET | 1100 | 2.875 |
01:55 ET | 17459 | 2.865 |
01:57 ET | 2118 | 2.865 |
02:00 ET | 928 | 2.865 |
02:02 ET | 1800 | 2.865 |
02:04 ET | 2014 | 2.87 |
02:06 ET | 4722 | 2.87 |
02:08 ET | 4890 | 2.87 |
02:09 ET | 4490 | 2.87 |
02:11 ET | 4101 | 2.87 |
02:13 ET | 9154 | 2.8799 |
02:15 ET | 6604 | 2.89 |
02:18 ET | 6796 | 2.89 |
02:20 ET | 5625 | 2.9 |
02:22 ET | 30325 | 2.89 |
02:24 ET | 2343 | 2.89 |
02:26 ET | 1500 | 2.885 |
02:27 ET | 1100 | 2.885 |
02:29 ET | 3780 | 2.885 |
02:31 ET | 39788 | 2.885 |
02:33 ET | 3761 | 2.9 |
02:36 ET | 2146 | 2.9 |
02:38 ET | 8729 | 2.89 |
02:40 ET | 8129 | 2.9 |
02:42 ET | 24341 | 2.91 |
02:44 ET | 18727 | 2.92 |
02:45 ET | 11432 | 2.92 |
02:47 ET | 22275 | 2.94 |
02:49 ET | 21951 | 2.94 |
02:51 ET | 8440 | 2.95 |
02:54 ET | 15421 | 2.95 |
02:56 ET | 23908 | 2.955 |
02:58 ET | 2074 | 2.955 |
03:00 ET | 2234 | 2.95 |
03:02 ET | 12273 | 2.96 |
03:03 ET | 8800 | 2.96 |
03:05 ET | 32802 | 2.935 |
03:07 ET | 8942 | 2.925 |
03:09 ET | 16745 | 2.93 |
03:12 ET | 3337 | 2.925 |
03:14 ET | 6594 | 2.93 |
03:16 ET | 245690 | 2.955 |
03:18 ET | 43265 | 2.95 |
03:20 ET | 46139 | 2.945 |
03:21 ET | 2478 | 2.945 |
03:23 ET | 177764 | 2.945 |
03:25 ET | 80212 | 2.945 |
03:27 ET | 114187 | 2.95 |
03:30 ET | 10790 | 2.94 |
03:32 ET | 118387 | 2.94 |
03:34 ET | 25689 | 2.935 |
03:36 ET | 20390 | 2.935 |
03:38 ET | 45800 | 2.9 |
03:39 ET | 13634 | 2.895 |
03:41 ET | 2700 | 2.89 |
03:43 ET | 14603 | 2.9 |
03:45 ET | 18352 | 2.905 |
03:48 ET | 39606 | 2.89 |
03:50 ET | 29336 | 2.9 |
03:52 ET | 126250 | 2.92 |
03:54 ET | 100062 | 2.935 |
03:56 ET | 127899 | 2.93 |
03:57 ET | 78508 | 2.89 |
03:59 ET | 12267824 | 2.89 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Erasca Inc | 839.0M | -3.1x | --- |
Terns Pharmaceuticals Inc | 847.4M | -7.6x | --- |
Arrivent Biopharma Inc | 812.8M | -10.1x | --- |
Oruka Therapeutics Inc | 868.7M | -4.2x | --- |
Dianthus Therapeutics Inc | 824.9M | -5.1x | --- |
89Bio Inc | 878.0M | -4.2x | --- |
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $839.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 282.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.92 |
Book Value | $2.10 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.